Nitroflurbiprofen (NicOx)

Current Opinion in Investigational Drugs

Volumn 5, Issue 5, 2004, Pages 551-556

  Scatena, Roberto ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG DERIVATIVE; FLURBIPROFEN; FLURBIPROFEN 4 NITROXYBUTYL ESTER; NITRIC OXIDE DONOR; PROSTAGLANDIN SYNTHASE INHIBITOR;

ALZHEIMER DISEASE; ANIMAL; ARTHRITIS; CLINICAL TRIAL; HUMAN; OSTEOPOROSIS; PAGET BONE DISEASE; REVIEW; STRUCTURE ACTIVITY RELATION; URINE INCONTINENCE; URTICARIA;

ALZHEIMER DISEASE; ANIMALS; ARTHRITIS; CLINICAL TRIALS; CYCLOOXYGENASE INHIBITORS; FLURBIPROFEN; HUMANS; NITRIC OXIDE DONORS; OSTEITIS DEFORMANS; OSTEOPOROSIS; STRUCTURE-ACTIVITY RELATIONSHIP; URINARY INCONTINENCE; URTICARIA;

EID: 3342984044     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. 210830 NicOx files. NicOx SA PRESS RELEASE 1996 June 12.
2. 220943 Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat. Wallace JL, Reuter B, Cicala C, McNight W, Grisham MB, Cirino G GASTROENTEROLOGY 1994 107 1 173-179
3. 224276 NO-NSAID: A new class of GI sparing nonsteroidal anti-inflammatory drugs. Cirino G, Del Soldato P, Robinson B, Wallace JL INT CONGR INFLAMM RES ASSOC 1996 8 Abs P70
4. 229295 Flurbinitroxybutylester: A novel anti-inflammatory drug has enhanced antithrombotic activity. Cirino G, Cicala C, Mancuso F, Baydoun AR, Wallace JL THROMB RES 1995 79 1 73-81
5. 243679 NicOx completes phase I clinical trial in UK of its anti-inflammatory HCT 1026. NicOx SA PRESS RELEASE 1997 April 25
6. 247995 Symposium on 'Newer, Safer NSAIDs' held in conjunction with Digestive Disease Week Washington DC, USA. IDDB MEETING REPORT 1997 May 10-14
7. 257936 Intestinal tolerability of nitroxybutyl-flurbiprofen in rats. Somasundaram S, Rafi S, Jacob M, Sigthorsson G, Mahmud T, Sherwood R, Price AB, Macpherson A, Scott D, Wrigglesworth JM, Bjarnason I GUT 1997 40 5 608-613
8. 258550 Brain-derived neurotrophic factor rescues developing avian motoneurons from cell death. Oppenheim RW, Yin QW, Prevette D, Yan Q NATURE 1992 360 6406 755-757
9. 261735 Antiproliferative effect of nonsteroidal antiinflammatory drugs against human colon cancer cells. Hixson LJ, Alberts DS, Krutzsch M, Einsphar J, Brendel K, Gross PH, Paranka NS, Baier M, Emerson S, Pamukcu R CANCER EPIDEMIOL BIOMARKERS PREV 1994 3 5 433-438
10. 288552 Nitroflurbiprofen, a new nonsteroidal anti-inflammatory, ameliorates structural injury in the remnant kidney. Fujihara CK, Malheiros DMAC, Donato JL, Poli A, De Nucci G, Zatz R AM J PHYSIOL -RENAL PHYSIOL 1998 274 3 Pt 2 F573-F579
11. 290035 Role of nitric oxide in gastrointestinal and hepatic function and disease. Stark ME, Szurszewski JH GASTROENTEROLOGY 1992 103 6 1928-1949
12. 290036 Nitric oxide donors: Biochemical, pharmacology and therapeutics. Bauer JA, Booth BP, Fung HL ADV PHARMACOL 1995 34 361-381
13. 295025 Nitric oxide donating flurbiprofen (HCT 1026) causes less endoscopic damage in healthy volunteers than flurbiprofen. Donnelly MT, Stack WA, Courtauld EM, Garlick N, Del Soldato P, Hawkey CJ GASTROENTEROLOGY 1998 114 4 Pt 2 A107
14. 333029 Prevention of chronic neuro-inflammation by NO-releasing flurbiprofen in a new animal model of Alzheimer's disease. Hauss-Wegrzyniak B, Wenk GL MEDIATORS INFLAMM 1999 8 Suppl 1 P-11-15
15. 334019 NicOx initiates phase IIa trial with HCT-1026 for urinary incontinence. NicOx SA PRESS RELEASE 1999 July 26
16. 344641 NicOx Corporate Profile. NicOx SA COMPANY BROCHURE 1999 October 25
17. 351194 NicOx initiates phase IIa trial with HCT-1026 in Paget's disease. NicOx SA PRESS RELEASE 1999 December 20
18. 359768 NicOx initiates human clinical trials in dermatology with HCT-1026. NicOx SA PRESS RELEASE 2000 March 15
19. 363794 NicOx granted CTX for HCT-1026 by UK Medicines Control Agency in urinary incontinence. NicOx SA PRESS RELEASE 2000 April 20
20. 373045 NicOx announces positive preliminary phase I/II results in contact urticaria - commences second dermatology study. NicOx SA PRESS RELEASE 2000 July 03
21. 391626 HCT 1026 shows positive clinical results in the treatment of skin inflammation. NicOx SA PRESS RELEASE 2000 November 28
22. 396119 NicOx: Harnessing the power of nitric oxide - Technology Update: NicOx SA, London UK. Brown H COMPANY PRESENTATION 2001 January 16
23. 399698 Opposite effects of flurbiprofen and the nitroxybutyl ester of flurbiprofen on apoptosis in cultured guinea-pig gastric mucous cells. Johal K, Hanson PJ BR J PHARMACOL 2000 130 4 811-818
24. 399993 Annual Report 1999: NicOx. NicOx SA ANNUAL REPORT 1999 December 31
25. 406181 NicOx's HCT-1026 shows positive clinical dermatology results in prolonged contact urticaria. NicOx SA PRESS RELEASE 2001 April 18
26. 409357 NO-NSAIDs alter cell kinetics in human colon cancer cell lines more efficiently than traditional NSAIDs. Williams JL, Hasan I, Borgo S, Castillo E, Traganos F, Rigas B GASTROENTEROLOGY 2001 120 5 Suppl 1 Abs 879
27. 445294 NicOx announces positive phase IIa clinical results for HCT 1026 in overactive bladder. NicOx SA PRESS RELEASE 2002 April 02
28. 449904 Nitric oxide-releasing NSAIDs inhibit interleukin-1β converting enzyme-like cysteine proteases and protect endothelial cells from apoptosis induced by TNFα. Fiorucci S, Santucci L, Federici B, Antonelli E, Distrutti E, Morelli O, Renzo GD, Coata G, Cirino G, Soldato PD, Morelli A ALIMENT PHARMACOL THER 1999 13 3 421-435
29. 480468 NicOx reports year-end 2002 financial results. NicOx SA PRESS RELEASE 2003 March 03
30. 489398 NicOx announces successful phase I clinical results with HCT 1026 in development for Alzheimer's disease. NicOx SA PRESS RELEASE 2003 May 13
31. 490909 Neurodegenerative Disorders - SMi's Third Annual Conference, London, UK. Davies J IDDB MEETING REPORT 2003 May 21-22
32. 494638 Nitric oxide-releasing nonsteroidal anti-inflammatory drugs: Novel gastrointestinal-sparing drugs. Bandarage UK, Janero DR MINI REV MED CHEM 2001 1 1 57-70
33. 507246 Metabolic profile of NO-flurbiprofen (HCT1026) in rat brain and plasma: A LC-MS study. Aldini G, Carini M, Orioli M, Facino RM, Wenk GL LIFE SCI 2002 71 13 1487-1500
34. 507247 NO-flurbiprofen maintains duodenal blood flow, enhances mucus secretion contributing to lower mucosal injury. Holm L, Phillipson M, Perry MA AM J PHYSIOL - GASTROINTEST LIVER PHYSIOL 2002 283 5 G1090-G1097
35. 507248 A nitric oxide-donating flurbiprofen derivative reduces neuroinflammation without interacting with galantamine in the rat. Wenk GL, Rosi S, McGann K, Hauss-Wegrzyniak B EUR J PHARMACOL 2002 453 2-3 319-324
36. 507249 Beneficial effects of NO-releasing derivative of flurbiprofen (HCT-1026) in rat model of vascular injury and restenosis. Maffia P, Ianaro A, Sorrentino R, Lippolis L, Maiello FM, del Soldato P, Ialenti A, Cirino G ARTERIOSCLEROSIS 2002 22 2 263-267
37. 507253 Inhibition of bone resorption in vitro and prevention of ovariectomy-induced bone loss in vivo by flurbiprofen nitroxybutylester (HCT1026). Armour KJ, van' t RJ, Armour KE, Torbergsen AC, Del Soldato P, Ralston SH ARTHRITIS RHEUM 2001 44 9 2185-2192
38. 2, interleukin-1β, and nitric oxide synthesis by activated microglia. Ajmone-Cat MA, Nicolini A, Minghetti L J NEUROSCI RES 2001 66 4 715-722
39. 507649 Biopartnering - NicOx SA. ANN BIOPARTENERING EUROPE MEET 2001 11 October 12-14
40. 509463 Anti-Inflammatory Therapeutics - SMi Conference, London, UK. Lunec A IDDB MEETING REPORT 2003 October 15-16
41. 509781 Nitric Oxide (NO) Based Anti-Inflammatory agents; New Effective Anti-Inflammatory Drugs Based on Contribution by NO. Ongini E SMI CONF - ANTIINFLAMM THER 2003 October 15-16
42. 512827 Cerebrospinal fluid concentration of flurbiprofen after multiple administrations of HCT 1026, a NO-donating derivative of flurbiprofen, in humans. Tocchetti P, Sardina M, Santus G, Casamenti F, Del Soldato P ABSTR SOC NEUROSCI 2003 33 Abs 525.12
43. 513790 Divergent effects of new cyclooxygenase inhibitors on gastric ulcer healing: Shifting the angiogenic balance. Ma L, del Soldato P, Wallace JL PROC NATL ACAD SCI USA 2002 99 20 13243-13247
44. 515842 Nitric Oxide. V. therapeutic potential of nitric oxide donors and inhibitors. Muscara MN, Wallace JL AM J PHYSIOL 1999 276 6 Pt 1 G1313-G1316
45. 517677 Inhibition of human brain tumor cell growth by the anti-inflammatory drug, flurbiprofen. King JG, Khalili K ONCOGENE 2001 20 47 6864-6870
46. 517680 E-7869 (R-flurbiprofen) inhibits progression of prostate cancer in the TRAMP mouse. Wechter WJ, Leipold DD, Murray ED, Quiggle D, McCracken JD, Barrios RS, Greenberg NM CANCER RES 2000 60 8 2203-2208
47. 517685 Asprin and other nonsteroidal antiinflammatory drugs and the risk of cancer development. Thun MJ, Hennekens CH CANCER: PRINCIPLES PRACTICE ONCOL Devita VT, Hellman S, Rosenberg SA (Eds), Lippincott Williams and Wilkins, Philadelphia, PA, USA 2001 5 602-606